$CLXPF News

Last published 5y ago

5y agoCLXPFCybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5Business WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received approval for the listing of its common shares on the NYSE American LLC stock ex
5y agoCLXPFCybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common SharesBusiness WireNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Cybin Inc. (NEO: CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, announced today the pri
5y agoATAI CLXPF CMPS MNMD+1Psychedelics -- Not Just for Mental Health AnymorePR NewswireNEW YORK, July 27, 2021 /PRNewswire/ -- In July 2012, Congress created what is known as Breakthrough Therapy designation, a distinction that affords biotechnology and pharmaceutical companies an expedited review process for experimental drugs that may ha
5y agoCLXPFCybin Announces Conditional Listing Approval from NYSE AmericanBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received conditional listing approval from the NYSE American LLC stock exchange (the "NY
5y agoCLXPFCybin Files its 13th Patent Application and Announces Digital Therapeutics StrategyBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed its 13th new provisional patent application and has advanced the build-out of its
5y agoCLXPFCybin to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13thBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be participating in a panel discussion at the Cowe
5y agoCLXPFCybin Expands to Europe and Provides Update on Intellectual Property PortfolioBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced the scaling up of its European operations and research activities with various academic and clinical
5y agoATAI CLXPF CMPS GBNH+2Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs MarketPR NewswirePALM BEACH, Fla., July 7, 2021 /PRNewswire/ -- Psychedelic drugs and therapies are truly becoming mainstream and are expected to become even more so in the years to come. Psychedelic drugs involve various types of chemical substances including LSD and ch
5y agoCLXPF GBNH TSX:GTMSCybin Enters into Collaboration Agreement with Greenbrook TMS to Establish Mental Health Centers of ExcellenceBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has entered into an exclusive research and development collaboration agreement (the "Collabo
5y agoARHH AVCRF BABYF CLXPF+9Life Sciences Companies Investor Presentations Now Available for On-Demand ViewingGlobeNewswireNEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the June 24th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased
5y agoCLXPFCybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone AchievementBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin, has achiev
5y agoCLXPF CTLT LHCybin Inc. Releases Annual Financials and Provides Business HighlightsBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today released financial and business highlights for its financial year ended March 31, 2021. Unless otherwise indic
5y agoCLXPFCybin to Participate in Grizzle Psychedelics Con on June 28thBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will participate in a virtual fireside chat at Grizzle
5y agoCLXPFCybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory BoardBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced the addition of Dr. Thomas Laughren, to the Clinical Advisory Board. Dr. Thomas Laughren formerly se
5y agoCLXPFCybin to Present at the Life Sciences Investor Forum on June 24thGlobeNewswireTORONTO, June 23, 2021 (GLOBE NEWSWIRE) -- Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be pr
5y agoCLXPFCybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule StudyBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced the completion of its 51st pre-clinical study as it continues to progress its proprietary psychedeli
5y agoARHH AVCRF BABYF CLXPF+9Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021GlobeNewswireNEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will s
5y agoCBDD CLXPF ERVFF FTXP+5CEO Presenting on the First Emerging Growth / Investors Hub Joint Conference on June 23. Register NowGlobeNewswireMIAMI, June 21, 2021 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 10th Emergi
5y agoCLXPFCybin to Present at the Emerging Growth Conference on June 23rdBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Emerging Growth Conference on
5y agoCLXPFCybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004Business WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has selected social anxiety disorder ("SAD") and generalized anxiety disorder ("GAD") as the
5y agoCLXPFCybin to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17thBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the H.C. Wainwright Psychedelics
5y agoCLXPF CMPS MNMD OPTHF+1Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several YearsPR NewswirePALM BEACH, Fla., June 8, 2021 /PRNewswire/ -- The illegal drugs of the 1960's are becoming highly valued drugs for various new therapeutic uses across a growing list of maladies. The door of previously prohibited drugs has been opening and it appears th
5y agoCLXPFCybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted PsychotherapyBusiness Wire-- EMBARK is a ground-breaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine -- Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused
5y agoCLXPFCybin to Present at the 2021 LD Micro Invitational XI on June 10, 2021Business WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the 2021 LD Micro Invitational XI. The presentation details
5y agoCLXPFCybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine's Psychedelic Effects on Cerebral Cortex HemodynamicsBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced the sponsorship of Kernel's feasibility study of its Kernel Flow technology to measure Ketamine's ps
5y agoCLXPFCybin to Present at the Jefferies Virtual Healthcare Conference 2021Business WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Jefferies Virtual Healthcare
5y agoCLXPFCybin Files an International Patent Application Further Strengthening its Psychedelic Derivative Drug Development Candidates Across 153 Global JurisdictionsBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed an international patent application that brings the potential to obtain patent cov
5y agoCLXPF CMPS MNMD SILOPsychedelic Drug Market Has Become a Billion Dollar Industry As Acceptable Treatments ExpandPR NewswirePALM BEACH, Fla., May 25, 2021 /PRNewswire/ -- Recently, the use of psychedelics is evolving for the treatment of a variety of mental illnesses, including anxiety, depression, post-traumatic stress disorder and other related uses. Some psychedelic drugs
5y agoCLXPFCybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery MechanismsBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed a new provisional patent application in support of its ongoing drug candidate prog
5y agoCLXPF CMPS FTRPF MNMD+1Wall Street Unicorns in Process of Changing the Healthcare LandscapePR NewswireNEW YORK, May 18, 2021 /PRNewswire/ -- Before 1970, promising research was being conducted on the potential therapeutic effects of a broad category of psychedelic drug compounds, including substances such as psilocybin, DMT (dimethyltryptamine), LSD (lys
5y agoCLXPFCybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive DisorderBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the Institutional Review Board ("IRB") at the University of the West Indies Hospital, in Jamaica has granted approval to c
5y agoCLXPF CMPS LLY MRK+1Psychedelics Move to The Forefront of Innovative Research as the FDA Approves Large-Scale TestingPR NewswireNEW YORK, May 13, 2021 /PRNewswire/ -- Psychedelics are quietly being used in clinical settings on small numbers of patients, but they are moving quickly toward medical approval. The FDA recently approved large-scale human trials to determine whether MD
5y agoCLXPFCybin to Present at the Benzinga Global Small Cap ConferenceBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Benzinga Global Small Cap Con
5y agoCLXPFCybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003Business WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has selected Alcohol Use Disorder ("AUD") as the initial target indication for its proprieta
5y agoCLXPF FTRPF MCURF MMEDFPsychedelic Drugs Market Size Is Projected To Reach $10.75 Billion By 2027PR NewswirePALM BEACH, Fla., April 21, 2021 /PRNewswire/ -- The psychedelics industry has entered the spotlight! The rapidly increasing acceptance of psychedelic treatments is creating a strong demand from therapists and patients for access to the new products an
5y agoCLXPFCybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and AddictionBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has successfully demonstrated Proof of Concept for its deuterated tryptamine programs, CYB00
5y agoCLXPFCybin to Present at the Bloom Burton & Co. Healthcare Investor ConferenceBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Bloom Burton & Co. Healthcare
5y agoCLXPFCybin Establishes Clinical Advisory Board of Renowned Physicians, Dr. Maurizio Fava, Dr. Lynn Marie Morski and Dr. Anthony BackBusiness WireCybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced the formation of its Clinical Advisory Board, with the additions of Maurizio Fava, MD, Psychiatrist-